Home

Have you been diagnosed with Pulmonary Arterial Hypertension?

If you’ve answered “yes”, you may be eligible for the PAH-001 : A phase 1 clinical trial of ABI-009, a targeted mTOR inhibitor, for patients with severe pulmonary arterial hypertension (PAH)

** The PAH-001:A phase 1 clinical trial of ABI-009, an mTOR inhibitor, for patients with severe pulmonary arterial hypertension (PAH) is enrolling patients at approximately 6 US study centers.

We Conduct 

Scientific Research in the PAH Field

About PAH

Pulmonary Arterial Hypertension (PAH) is a type of a broader condition known as pulmonary hypertension, which means high blood pressure in…

The Study

This study will evaluate the optimal dose, safety, and potential therapeutic benefits of an experimental medication to treat PAH. Everyone in the study….

Clinical Research

A clinical research study is a carefully designed scientific evaluation of an investigational medication conducted by physicians. Clinical research studies….